Can FDG-PET after neoadjuvant chemotherapy plus nivolumab predict residual disease in non-small cell lung cancer?

被引：0

作者：

Iguchi, Hideto ^{[1
]}

Akamatsu, Hiroaki ^{[2
]}

Hirai, Yoshimitsu ^{[1
]}

Nakaya, Takahito ^{[1
]}

Fusamoto, Aya ^{[1
]}

Yata, Yumi ^{[1
]}

Nagai, Takahiro ^{[2
]}

Kitahara, Daiki ^{[2
]}

Takakura, Toshiaki ^{[2
]}

Nishimura, Yoshiharu ^{[1
]}

Yamamoto, Nobuyuki ^{[2
]}

机构：

[1] Wakayama Med Univ, Dept Thorac & Cardiovasc Surg, Wakayama, Japan

[2] Wakayama Med Univ, Internal Med 3, 811-1 Kimiidera, Wakayama 6418509, Japan

来源：

RESPIROLOGY CASE REPORTS | 2024年 / 12卷 / 08期

关键词：

FDG-PET; ICI; lung cancer; neoadjuvant therapy; nivolumab;

D O I：

10.1002/rcr2.70007

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Neoadjuvant therapy with nivolumab improves event-free survival (EFS) in patients with resectable non-small cell lung cancer, and a pathological complete response is a predictor of longer EFS. We assessed metabolic responses using 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) before and after neoadjuvant treatment to explore its surrogacy for pathological complete response (pCR). We describe three patients with squamous cell lung carcinoma who underwent neoadjuvant therapy with nivolumab plus chemotherapy, followed by surgery. In Cases 1 and 2, preoperative tumour response were PR per RECIST and demonstrated marked metabolic response on FDG-PET after neoadjuvant therapy, with both resected tumours showing a pCR. On the other hand, Case 3 showed a tumour response before surgery (PR per RECIST), however, the tumour, maintained FDG uptake (19.5 -> 15.1), and the resected tumour remained residual cells (RVT, 15%). Thus, reduction of FDG uptake on FDG-PET can predict the pathological response to neoadjuvant therapy with nivolumab.

引用

页数：4

共 9 条

[1] Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer [J].

Cascone, Tina ;

Weissferdt, Annikka ;

Godoy, Myrna C. B. ;

William, William N., Jr. ;

Leung, Cheuk H. ;

Lin, Heather Y. ;

Basu, Sreashi ;

Yadav, Shalini S. ;

Pataer, Apar ;

Mitchell, Kyle G. ;

Khan, Md Abdul Wadud ;

Shi, Yushu ;

Haymaker, Cara ;

Solis, Luisa M. ;

Parra, Edwin R. ;

Kadara, Huam ;

Wistuba, Ignacio I. ;

Sharma, Padmanee ;

Allison, James P. ;

Ajami, Nadim J. ;

Wargo, Jennifer A. ;

Jenq, Robert R. ;

Gibbons, Don L. ;

Lee, J. Jack ;

Swisher, Stephen G. ;

Vaporciyan, Araa ;

Heymach, John, V ;

Sepesi, Boris .

NATURE COMMUNICATIONS, 2021, 12 (01)

[2] Association between pathologic response and survival after neoadjuvant therapy in lung cancer [J].

Deutsch, Julie Stein ;

Cimino-Mathews, Ashley ;

Thompson, Elizabeth ;

Provencio, Mariano ;

Forde, Patrick M. ;

Spicer, Jonathan ;

Girard, Nicolas ;

Wang, Daphne ;

Anders, Robert A. ;

Gabrielson, Edward ;

Illei, Peter ;

Jedrych, Jaroslaw ;

Danilovae, Ludmila ;

Sunshinee, Joel ;

Kerr, Keith M. ;

Tran, Mia ;

Bushong, Judith ;

Cai, Junliang ;

Devas, Vipul ;

Neely, Jaclyn ;

Balli, David ;

Cottrell, Tricia R. ;

Barase, Alex S. ;

Taube, Janis M. .

NATURE MEDICINE, 2024, 30 (01) :218-+

[3] Neoadjuvant PD-1 Blockade in Resectable Lung Cancer [J].

Forde, P. M. ;

Chaft, J. E. ;

Smith, K. N. ;

Anagnostou, V. ;

Cottrell, T. R. ;

Hellmann, M. D. ;

Zahurak, M. ;

Yang, S. C. ;

Jones, D. R. ;

Broderick, S. ;

Battafarano, R. J. ;

Velez, M. J. ;

Rekhtman, N. ;

Olah, Z. ;

Naidoo, J. ;

Marrone, K. A. ;

Verde, F. ;

Guo, H. ;

Zhang, J. ;

Caushi, J. X. ;

Chan, H. Y. ;

Sidhom, J. -W. ;

Scharpf, R. B. ;

White, J. ;

Gabrielson, E. ;

Wang, H. ;

Rosner, G. L. ;

Rusch, V. ;

Wolchok, J. D. ;

Merghoub, T. ;

Taube, J. M. ;

Velculescu, V. E. ;

Topalian, S. L. ;

Brahmer, J. R. ;

Pardoll, D. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (21) :1976-1986

[4] Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer [J].

Forde, Patrick M. ;

Spicer, Jonathan ;

Lu, Shun ;

Provencio, Mariano ;

Mitsudomi, Tetsuya ;

Awad, Mark M. ;

Felip, Enriqueta ;

Broderick, Stephen R. ;

Brahmer, Julie R. ;

Swanson, Scott J. ;

Kerr, Keith ;

Wang, Changli ;

Ciuleanu, Tudor-Eliade ;

Saylors, Gene B. ;

Tanaka, Fumihiro ;

Ito, Hiroyuki ;

Chen, Ke-Neng ;

Liberman, Moishe ;

Vokes, Everett E. ;

Taube, Janis M. ;

Dorange, Cecile ;

Cai, Junliang ;

Fiore, Joseph ;

Jarkowski, Anthony ;

Balli, David ;

Sausen, Mark ;

Pandya, Dimple ;

Calvet, Christophe Y. ;

Girard, Nicolas .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (21) :1973-1985

[5] Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors [J].

Gkiozos, Ioannis ;

Kopitopoulou, Alexandra ;

Kalkanis, Alexandros ;

Vamvakaris, Ioannis N. ;

Judson, Marc A. ;

Syrigos, Konstantinos N. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) :1076-1082

[6] Lung Cancer Recurrence: 18F-FDG PET/CT in Clinical Practice [J].

Kandathil, Asha ;

Sibley, Robert Carson, III ;

Subramaniam, Rathan M. .

AMERICAN JOURNAL OF ROENTGENOLOGY, 2019, 213 (05) :1136-1144

[7] Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade [J].

Stein, Julie E. ;

Lipson, Evan J. ;

Cottrell, Tricia R. ;

Forde, Patrick M. ;

Anders, Robert A. ;

Cimino-Mathews, Ashley ;

Thompson, Elizabeth D. ;

Allaf, Mohamad E. ;

Yarchoan, Mark ;

Feliciano, Josephine ;

Wang, Hao ;

Jaffee, Elizabeth M. ;

Pardoll, Drew M. ;

Topalian, Suzanne L. ;

Taube, Janis M. .

CLINICAL CANCER RESEARCH, 2020, 26 (03) :545-551

[8] The accuracy of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review [J].

Tian, Fangfang ;

Shen, Guohua ;

Deng, Yunfu ;

Diao, Wei ;

Jia, Zhiyun .

EUROPEAN RADIOLOGY, 2017, 27 (11) :4786-4796

[9] 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer [J].

Vallius, Tuulia ;

Peter, Anniina ;

Auranen, Annika ;

Carpen, Olli ;

Kemppainen, Jukka ;

Matomaki, Jaakko ;

Oksa, Sinikka ;

Roering, Pia ;

Seppanen, Marko ;

Grenman, Seija ;

Hynninen, Johanna .

GYNECOLOGIC ONCOLOGY, 2016, 140 (01) :29-35

← 1 →